Literature DB >> 27365533

Plastic restriction of HIV-1 replication in human macrophages derived from M1/M2 polarized monocytes.

Francesca Graziano1, Elisa Vicenzi2, Guido Poli3,4,5.   

Abstract

M1/M2 cytokine-dependent polarization of primary human MDMs has been shown to contain CCR5-dependent (R5) HIV-1 replication. In this study, a similar effect was achieved when monocytes were first polarized toward M1 or M2 and were infected 7 d after their differentiation into MDMs, regardless of whether the cytokines were removed 18 h after cell stimulation or were left in culture. Unlike polarized MDMs, no significant down-regulation of CD4 from the cell surface was observed in MDMs derived from M1/M2-polarized monocytes. A second stimulation of MDMs differentiated from M1/M2 monocytes with the opposite polarizing cytokines converted the virus replication profile according to the new stimuli. The expression of M1 and M2 markers (i.e., APOBEC3A and DC-SIGN, respectively) was induced by MDM stimulation with the opposite cytokines, although it also persisted in cells according to their first stimulatory condition. Thus, stimulation of monocytes with M1- and M2-inducing cytokines leads to a restriction of HIV-1 replication when these cells are infected several days later as differentiated MDMs. These observations imply that activation of circulating monocytes significantly influences their capacity to either support or restrict HIV-1 replication, once extravasated, and eventually to become infected as tissue macrophages. © Society for Leukocyte Biology.

Entities:  

Keywords:  APOBEC3A/3G; CD4; DC-SIGN; viral entry; viral latency

Mesh:

Substances:

Year:  2016        PMID: 27365533     DOI: 10.1189/jlb.4AB0316-158R

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  9 in total

1.  Chronic Viral Neuroinflammation: Speculation on Underlying Mechanisms.

Authors:  Elizabeth C Delery; Andrew G MacLean
Journal:  Viral Immunol       Date:  2018-09-27       Impact factor: 2.257

Review 2.  HIV Latency in Myeloid Cells: Challenges for a Cure.

Authors:  Alisha Chitrakar; Marta Sanz; Sanjay B Maggirwar; Natalia Soriano-Sarabia
Journal:  Pathogens       Date:  2022-05-24

3.  HIV Infection of Macrophages: Implications for Pathogenesis and Cure.

Authors:  Kiera L Clayton; J Victor Garcia; Janice E Clements; Bruce D Walker
Journal:  Pathog Immun       Date:  2017-05-24

4.  APOBEC3G/3A Expression in Human Immunodeficiency Virus Type 1-Infected Individuals Following Initiation of Antiretroviral Therapy Containing Cenicriviroc or Efavirenz.

Authors:  Daniela A Covino; Cristina Purificato; Laura Catapano; Clementina M Galluzzo; Maria Cristina Gauzzi; Stefano Vella; Eric Lefebvre; Star Seyedkazemi; Mauro Andreotti; Laura Fantuzzi
Journal:  Front Immunol       Date:  2018-08-08       Impact factor: 7.561

Review 5.  The HIV Reservoir in Monocytes and Macrophages.

Authors:  Michelle E Wong; Anthony Jaworowski; Anna C Hearps
Journal:  Front Immunol       Date:  2019-06-26       Impact factor: 7.561

6.  In vitro Phenotype Induction of Circulating Monocytes: CD16 and CD163 Analysis.

Authors:  Claudio Karsulovic; Fabian Tempio; Mercedes Lopez; Julia Guerrero; Annelise Goecke
Journal:  J Inflamm Res       Date:  2021-01-26

7.  Ganoderma lucidum Spore Polysaccharide Inhibits the Growth of Hepatocellular Carcinoma Cells by Altering Macrophage Polarity and Induction of Apoptosis.

Authors:  Ming Song; Zhen-Hao Li; Hong-Shun Gu; Ru-Ying Tang; Rui Zhang; Ying-Li Zhu; Jin-Lian Liu; Jian-Jun Zhang; Lin-Yuan Wang
Journal:  J Immunol Res       Date:  2021-03-05       Impact factor: 4.818

Review 8.  The Role of APOBECs in Viral Replication.

Authors:  Wendy Kaichun Xu; Hyewon Byun; Jaquelin P Dudley
Journal:  Microorganisms       Date:  2020-11-30

9.  Development of a Novel In Vitro Primary Human Monocyte-Derived Macrophage Model To Study Reactivation of HIV-1 Transcription.

Authors:  Anna C Hearps; Anthony Jaworowski; Michelle E Wong; Chad J Johnson
Journal:  J Virol       Date:  2021-09-09       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.